首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1917902

細胞冷凍保存市場－2026-2031年預測

Cell Freezing Market - Forecast from 2026 to 2031

出版日期: 2026年01月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

細胞冷凍保存市場預計將以 7.9% 的複合年成長率成長，到 2025 年達到 302,566,000 美元，到 2031 年達到 477,361,000 美元。

細胞冷凍市場（包括冷凍保存培養基、設備及相關耗材）是生命科學和生物技術產業中一個基礎且快速成長的細分市場。冷凍保存是將細胞儲存在超低溫（通常低於-80°C或液態氮中）以終止所有生物活性並確保其長期存活和功能的過程。這項技術對於保存珍貴的生物材料至關重要，從研究細胞株和原代細胞到治療性細胞產品均包含在內。細胞療法的進步、生物生物銀行基礎設施的不斷改進、保存通訊協定技術的持續改進以及慢性疾病的日益增多（推動了細胞研究的發展）共同驅動著市場擴張。

細胞療法的加速研發和商業化是推動這一領域發展的關鍵且強大的動力。再生醫學、免疫療法和幹細胞療法等領域從根本上依賴可靠的冷凍保存技術。 CAR-T細胞療法、間質幹細胞療法和其他先進治療藥物（ATMP）等療法需要保存、運輸和分發活細胞材料，同時確保其效力和功能不受影響。細胞冷凍保存技術是治療研發和交付過程中不可或缺的組成部分，它能夠實現現成的異體療法，並確保自體療法的可靠供應鏈。

同時，全球生物銀行活動的擴張和規模化也帶動了市場發展。用於學術研究、藥物研發、臨床試驗和人群健康研究的生物樣本庫都依賴可靠的長期細胞儲存。保存患者來源細胞、基因工程細胞株和疾病模型對於生物醫學發現至關重要。機構、政府和私人對生物銀行基礎設施的投資直接轉化為對高品質冷凍保存培養基、專用儲存容器和可靠的低溫儲存系統的持續需求。

冷凍保護劑（CPA）和冷凍技術的進步是推動市場成長和應用拓展的關鍵因素。研究重點在於開發毒性較低、無血清，甚至在某些情況下不含二甲基亞碸（DMSO）的冷凍保存培養基，從而提高解凍後細胞的活力、恢復率和功能性。此外，一些創新技術也在研發中，例如可控冷卻裝置，這些裝置能夠最佳化冷卻曲線，最大限度地減少冰晶形成和細胞損傷。對於臨床和治療應用而言，制定標準化的GMP級冷凍通訊協定尤其重要，因為在這些應用中，一致性和合規性至關重要。

全球慢性病和退化性疾病的日益增多，雖然是間接但卻重要的市場促進因素。癌症、心血管疾病、神經退化性疾病、糖尿病等疾病的研究擴大採用細胞模型、患者來源樣本和基於細胞的篩檢平台。這種活性化的研究活動產生了大量寶貴的細胞材料，這些材料需要保存以用於長期研究、實驗重複和未來應用，從而推動了學術界和工業界實驗室對可靠的冷凍保存解決方案的需求。

政府和機構對生命科學研究的支持也進一步推動了市場發展。用於幹細胞研究、再生醫學和個人化醫療的公共資助方案通常包含支援核心設施的條款，例如生物銀行和冷凍保存能力，這促進了先進冷凍保存技術的應用，並為長期細胞儲存的營運成本提供了支持。

北美憑藉其高度集中的生物技術和製藥公司、眾多知名學術研究機構、成熟的細胞治療研發生態系統以及對生命科學研發的大量投入，保持著區域主導地位。該地區對新技術的早期應用以及對臨床級材料品質標準的嚴格把控，鞏固了其作為先進細胞冷凍產品和服務最大市場的地位。

儘管成長要素強勁，但市場仍面臨一些技術和營運方面的挑戰。傳統的冷凍保護劑，例如二甲基亞碸（DMSO），雖然有效，但對於某些敏感細胞類型和臨床應用而言，其毒性問題仍令人擔憂，因此需要改進配方。此外，冷凍保存是一項技術複雜的過程，成功與否取決於精確的通訊協定流程，這需要訓練有素的人員和標準化的工作流程。凍融過程中的不一致會導致細胞回收率不穩定，進而影響實驗和治療效果，凸顯了加強訓練和標準化產品的重要性。

競爭格局包括生命科學試劑供應商、專業冷凍保存培養基公司和低溫儲存設備製造商。差異化優勢體現在產品性能（解凍後細胞存活率）、配方創新（不含動物源成分的即用型培養基）、可擴展性、法規遵從性（提供GMP文件）以及提供包含培養基、通訊協定，甚至在某些情況下還包括設備在內的完整解決方案。

總之，細胞冷凍市場正從一項基礎實驗室技術發展成為支撐未來醫療保健和藥物研發的關鍵工業化流程。其成長與細胞療法的進步以及生物樣本在研究中日益成長的價值密不可分。未來的發展將受到以下因素的影響：新一代冷凍保護劑的持續創新、自動化和封閉式流程的整合以提高可重複性，以及治療性細胞冷凍保存全球標準的建立。隨著生物經濟的擴張，可靠地「暫停」和重新啟動活細胞的能力仍將是一項基礎性技術，確保該市場在生命科學價值鏈中保持核心地位並不斷提升。

本報告的主要優勢：

深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在動態環境中製定策略決策，發展新的業務流和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

本報告的使用範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

The cell freezing market, encompassing cryopreservation media, equipment, and associated consumables, is a foundational and growing segment within the life sciences and biotechnology industries. Cryopreservation is the process of preserving cells at ultra-low temperatures, typically below -80°C or in liquid nitrogen, to halt all biological activity and ensure long-term viability and functionality. This technology is critical for preserving valuable biological materials, from research cell lines and primary cells to therapeutic cell products. The market's expansion is driven by the advancement of cell-based therapies, the growing infrastructure for biobanking, continuous technological improvements in preservation protocols, and the rising prevalence of chronic diseases that fuel cellular research.

A primary and powerful driver is the accelerating development and commercialization of cell-based therapies. The fields of regenerative medicine, immunotherapy, and stem cell therapy are fundamentally reliant on robust cryopreservation. Therapies such as CAR-T cells, mesenchymal stem cell treatments, and other advanced therapeutic medicinal products (ATMPs) require that living cellular material be stored, transported, and distributed without loss of potency or function. Cell freezing enables the creation of off-the-shelf allogeneic therapies and ensures the reliable supply chain for autologous treatments, making it an indispensable component of the therapeutic development and delivery pipeline.

Concurrently, the market benefits from the expanding scope and scale of biobanking activities worldwide. Biorepositories for academic research, pharmaceutical R&D, clinical trials, and population health studies all depend on high-integrity, long-term cell storage. The preservation of patient-derived cells, genetically engineered lines, and disease models is essential for biomedical discovery. Institutional, government, and commercial investments in biobanking infrastructure directly translate into sustained demand for high-quality cryopreservation media, specialized storage containers, and reliable cryogenic storage systems.

Technological advancements in cryoprotective agents (CPAs) and freezing methodologies are critical enablers of market growth and application expansion. Research focuses on improving post-thaw cell viability, recovery, and functionality by developing less toxic, serum-free, and sometimes DMSO-free cryopreservation media. Innovations also include controlled-rate freezing equipment that optimizes the cooling curve to minimize ice crystal formation and cellular damage. The development of standardized, GMP-grade freezing protocols is particularly important for clinical and therapeutic applications, where consistency and regulatory compliance are paramount.

The rising global burden of chronic and degenerative diseases acts as an indirect yet significant market driver. Research into conditions such as cancer, cardiovascular disease, neurodegenerative disorders, and diabetes increasingly utilizes cellular models, patient-derived samples, and cell-based screening platforms. This research intensity generates substantial volumes of valuable cellular material that must be preserved for longitudinal studies, replication of experiments, and future use, thereby fueling demand for reliable cryopreservation solutions across academic and industrial laboratories.

Governmental and institutional support for life sciences research further stimulates the market. Public funding initiatives for stem cell research, regenerative medicine, and personalized medicine often include provisions for supporting core facilities, which encompass biobanking and cryopreservation capabilities. This funding environment encourages the adoption of advanced freezing technologies and supports the operational costs of long-term cell storage.

Geographically, North America maintains a leading position, driven by a concentration of biotechnology and pharmaceutical companies, leading academic research institutions, a mature ecosystem for cell therapy development, and significant investment in life sciences R&D. The region's early adoption of new technologies and stringent focus on quality standards for clinical-grade materials reinforces its role as the largest market for sophisticated cell freezing products and services.

Despite strong growth drivers, the market faces specific technical and operational challenges. The toxicity of traditional cryoprotectants like DMSO, though effective, remains a concern for some sensitive cell types and clinical applications, driving the need for improved formulations. Furthermore, cryopreservation is a technically demanding process; successful outcomes depend on precise protocol execution, requiring trained personnel and standardized workflows. Inconsistencies in freezing or thawing can lead to variable cell recovery and compromised experimental or therapeutic results, highlighting the need for robust training and standardized products.

The competitive landscape includes life science reagent suppliers, specialized cryopreservation media companies, and manufacturers of cryogenic storage equipment. Differentiation is based on product performance (post-thaw viability), formulation innovation (e.g., animal-component-free, ready-to-use media), scalability, regulatory support (GMP documentation), and the provision of comprehensive solutions that include media, protocols, and sometimes equipment.

In conclusion, the cell freezing market is evolving from a basic laboratory technique to a critical, industrialized process underpinning the future of medicine and discovery. Its growth is inextricably linked to the progress of cell therapy and the expanding value of biological samples in research. Future development will be shaped by the continued innovation of next-generation cryoprotectants, the integration of automation and closed-system processing to enhance reproducibility, and the establishment of global standards for the cryopreservation of therapeutic cells. As the bioeconomy expands, the ability to reliably "pause" and restart living cells will remain a cornerstone capability, ensuring the market's central and growing role in the life sciences value chain.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Cell Freezing Market Segmentation

By Media Type
Glycerol
Dimethyl Sulfoxide (DMSO)
By Application
Stem Cells
Mammalian Cells
Others
By End-User
Pharmaceutical & Biotech Companies
Academic & Research Institutes
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELL FREEZING MARKET BY MEDIA TYPE

5.1. Introduction
5.2. Glycerol
5.3. Dimethyl Sulfoxide (DMSO)

6. CELL FREEZING MARKET BY APPLICATION

6.1. Introduction
6.2. Stem Cells
6.3. Mammalian Cells
6.4. Others

7. CELL FREEZING MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Academic & Research Institutes
7.4. Others

8. CELL FREEZING MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others